Vaccine comprising glycoprotein D (gD2t) against herpes simplex virus (HSV)

Herpes simplex virus glycoprotein D and an adjuvant can be used to prepare a vaccine formulation for HSV seronegative females to prevent HSV infection. The HSV gD may further be a truncated protein that is devoid of its C-terminal anchor region (gD2t). The adjuvant may be the TH-1 adjuvant 3-DMPL an...

Full description

Saved in:
Bibliographic Details
Main Authors VANDEPAPELIERE, PIERRE, SLAOUI, MONCEF MOHAMMED
Format Patent
LanguageEnglish
Published 29.04.2003
Edition7
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Herpes simplex virus glycoprotein D and an adjuvant can be used to prepare a vaccine formulation for HSV seronegative females to prevent HSV infection. The HSV gD may further be a truncated protein that is devoid of its C-terminal anchor region (gD2t). The adjuvant may be the TH-1 adjuvant 3-DMPL and the vaccine formulation may further comprise an aluminum salt.
Bibliography:Application Number: NZ19990510425